Clinical Study Data Presentation, Product Launches, Technology Deployments, and Stock Price Movements - Research Report on

 Clinical Study Data Presentation, Product Launches, Technology Deployments,
and Stock Price Movements - Research Report on Celgene, Mylan, Valeant, Health
                          Management, and CareFusion

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, December 17, 2013

NEW YORK, December 17, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Celgene
Corporation (NASDAQ: CELG), Mylan Inc. (NASDAQ: MYL), Valeant Pharmaceuticals
International Inc. (NYSE: VRX), Health Management Associates Inc. (NYSE: HMA),
and CareFusion Corporation (NYSE: CFN). Today's readers may access these
reports free of charge - including full price targets, industry analysis and
analyst ratings - via the links below.

Celgene Corporation Research Report

On December 10, 2013, Celgene Corporation's (Celgene) wholly owned subsidiary,
Celgene International Sàrl, announced that it has presented updated analyses
from MM-003, at the American Society of Hematology Annual Meeting in New
Orleans, Louisiana. According to the Company, the MM-003 is a phase III study
of pomalidomide plus low-dose dexamethasone, compared with high-dose
dexamethasone in patients with refractory multiple myeloma who have failed
therapy with both bortezomib and lenalidomide, administered either alone or in
combination. According to Celgene, it previously reported that with a median
follow-up of 10 months, pomalidomide plus low-dose dexamethasone significantly
extended progression-free survival (PFS) (4.0 months vs. 1.9 months, HR=-0.48,
p<0.001) and overall survival (OS) (12.7 months vs. 8.1 months, HR= 0.74,
p<0.028) compared with high-dose dexamethasone. Celgene informed that the OS
benefit was observed despite 50% of the patients in the high-dose
dexamethasone arm receiving subsequent pomalidomide. Further, Celgene informed
that in a retrospective analysis, the increase in ORR and median PFS were
maintained for pomalidomide plus low-dose dexamethasone compared with
high-dose dexamethasone regardless of modified high-risk cytogenetics (del
(17p) or t(4;14)) (ORR: 25% vs. 9%, P=0.071; PFS: 3.8 vs. 1.1 months, HR=0.44,
P<0.001) or standard-risk cytogenetics (ORR: 35% vs. 10%, P<0.001; PFS: 4.2
vs. 2.3 months, HR=0.55, P<0.001). The Full Research Report on Celgene
Corporation - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/7f47_CELG

--

Mylan Inc. Research Report

On December 5, 2013, Mylan Inc. (Mylan) announced that the Company's U.S.
based subsidiary, Mylan Pharmaceuticals Inc., launched Cabergoline Tablets
USP, 0.5 mg, which are indicated for the treatment of hyperprolactinemic
disorders, either idiopathic or due to pituitary adenomas. Mylan informed that
it has received approval from the US Food and Drug Administration (FDA) for
its Abbreviated New Drug Application (ANDA) for 0.5mg Cabergoline Tablets USP.
The Full Research Report on Mylan Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

http://www.analystscorner.com/r/full_research_report/5a20_MYL

--

Valeant Pharmaceuticals International Inc. Research Report

On December 12, 2013, Valeant Pharmaceuticals International Inc.'s (Valeant)
stock declined 0.23%, ending the day's session at $106.24. Over the previous
three trading sessions, shares of Valeant declined 1.60%, compared to the S&P
500 which declined 1.82% during the same period. The Full Research Report on
Valeant Pharmaceuticals International Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

http://www.analystscorner.com/r/full_research_report/9fdd_VRX

--

Health Management Associates Inc. Research Report

On December 12, 2013, Health Management Associates Inc.'s (Health Management)
stock rose 0.23%, ending the day's session at $13.00. Over the previous three
trading sessions, shares of Health Management declined 0.61%, compared to the
S&P 500 which declined 1.82% during the same period. The Full Research Report
on Health Management Associates Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

http://www.analystscorner.com/r/full_research_report/9ce8_HMA

--

CareFusion Corporation Research Report

On December 11, 2013, CareFusion Corporation (CareFusion) reported that Olathe
Health System has rolled out new technology, designed to help improve
medication safety at the Olathe Medical Center and Miami County Medical
Center. The Company informed that the new technology from CareFusion and
Cerner is designed to help hospitals reduce medication administration errors
by enabling nurses to pre-program intravenous (IV) medication orders from the
hospitals' Cerner Millennium electronic health record (EHR) system to the
CareFusion Alaris System smart infusion pump through barcode scanning at the
patient bedside. The Company added that the CareFusion Alaris System and the
Cerner CareAware iBus can reduce the number of manual steps required to
program an infusion order from as many as 22 key presses down to two or three
confirmation steps. The Full Research Report on CareFusion Corporation -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/4933_CFN

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Nidhi Vatsal, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.